Accessibility Menu
Ikena Oncology logo

Ikena Oncology(NASDAQ) IKNA

This security has been delisted. This page is retained for historical reference.

Ikena Oncology last closing stock price
MetricPriceDate
Last closeUSD 5.642026-08-03
Ikena Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.71%USD 5.602026-07-27
1 month-3.26%USD 5.832026-07-02
3 month-3.26%USD 5.832026-05-05
Year to date-18.26%USD 6.902025-12-31
1 year-67.36%USD 17.282025-08-01
3 year-90.47%USD 59.162023-08-04
5 year-95.3%USD 120.002021-08-04
Since inception-95.53%USD 384.002021-03-26

IKNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

IKNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-35.20%

Return on Capital

-63.93%

Return on Assets

-32.98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$87.00K

Operating Income

-$49.74M

EBITDA

$9.77M

Operating Cash Flow

-$52.08M

Capital Expenditure

$0.00

Free Cash Flow

-$52.08M

Cash & ST Invst.

$117.21M

Total Debt

$2.42M

Ikena Oncology Performance Analysis

Ikena Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 15,618,000-49.6%
20232023-12-31USD 9,160,000-41.3%
20242024-12-31USD 3,500,000-61.8%
20252025-12-31USD 800,000-77.1%
Ikena Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Ikena Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -22.80100.4%
20232023-12-31USD -19.60-14.0%
20242024-12-31USD -40.52106.7%
20252025-12-31USD -9.64-76.2%
Ikena Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3068.2%
Q32025-09-30-825.0%
Q42025-12-31245.3%
Q12026-03-31-223.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

10

N/A

Net Income

-$10.62M

-23.2%

EBITDA

$174.00K

+101.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$117.21M

+2.8%

Total Debt

$2.42M

-63.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$110.00K

-96.0%

Short Term Debt

$2.31M

-40.8%

Return on Assets

-32.98%

N/A

Return on Invested Capital

-43.00%

N/A

Free Cash Flow

-$14.80M

-40.1%

Operating Cash Flow

-$14.80M

-40.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ASLNASLAN Pharmaceuticals Limited
$0.60-14.27%
EXAIExscientia plc
$4.84N/A
ICVXIcosavax, Inc.
$15.31-0.91%
CDMOAvid Bioservices, Inc.
$12.49+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
AMIXAutonomix Medical
$19.04+4.22%
SPCXSpace Exploration Technologies
$125.52+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.08+0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.